Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $229K | $239K | $318K | $530K | $623K | $1.70M | $752K | $2.28M | $2.56M | $2.55M |
| Revenue growth | — | 4.4% | 33.1% | 66.7% | 17.5% | 172.1% | -55.6% | 203.6% | 12.0% | -0.2% |
| Gross profit | $141K | $151K | $160K | $281K | $214K | $770K | $167K | $1.54M | $1.51M | $153K |
| Gross margin | 61.6% | 63.2% | 50.3% | 53.0% | 34.3% | 45.4% | 22.2% | 67.3% | 59.0% | 6.0% |
| Operating income | -$2.32M | -$3.09M | -$4.30M | -$5.15M | -$4.72M | -$5.68M | -$5.01M | -$3.44M | -$3.58M | -$22.9M |
| Operating margin | -1011.4% | -1293.3% | -1353.1% | -971.9% | -757.5% | -335.3% | -666.5% | -150.5% | -140.0% | -896.6% |
| Net income | -$2.83M | -$4.96M | -$4.15M | -$5.79M | -$4.33M | -$14.3M | -$5.45M | -$3.71M | -$3.71M | -$18.2M |
| Net margin | -1236.2% | -2077.4% | -1306.3% | -1093.2% | -694.4% | -842.6% | -724.5% | -162.5% | -144.8% | -712.3% |
| EPS (diluted) | -$0.62 | -$1.17 | -$0.64 | -$0.83 | -$0.42 | -$0.57 | -$3.84 | -$23.32 | -$137.30 | -$26.69 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.53M | -$2.18M | -$3.55M | -$3.87M | -$3.39M | -$4.37M | -$7.04M | -$3.60M | -$2.52M | -$9.37M |
| Capital expenditures | $8.00K | — | $8.00K | — | $2.00K | $3.00K | $3.00K | $1.00K | $3.00K | $60.0K |
| Free cash flow | -$1.54M | — | -$3.56M | — | -$3.39M | -$4.37M | -$7.04M | -$3.60M | -$2.52M | -$9.43M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $106K | $4.36M | $896K | $1.34M | $7.14M | $7.74M | $2.71M | $3.28M | $752K | $4.22M |
| Total assets | $494K | $4.87M | $1.58M | $2.04M | $8.23M | $8.62M | $5.88M | $6.67M | $3.63M | $41.1M |
| Total liabilities | — | — | $1.12M | $688K | $5.83M | $2.31M | $2.65M | $2.69M | $3.00M | $7.63M |
| Shareholders' equity | -$2.50M | $3.63M | $463K | $1.35M | $2.39M | $6.31M | $3.23M | $3.99M | $627K | $33.5M |
| Retained earnings | -$22.6M | -$28.4M | -$32.5M | -$38.3M | -$42.7M | -$56.9M | -$62.4M | -$66.1M | -$69.8M | -$90.5M |
| Shares (wtd avg diluted) | 2.63M | 3.94M | 3.80M | 4.20M | 19.9M | 1.26M | 1.42M | 159K | 27.0B | 629K |
Every figure is extracted from ENvue Medical, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.